Prenuvo

Prenuvo, founded in 2018, builds the technical and clinical foundation for proactive whole-body MRI screening. Its service detects serious conditions such as cancer and aneurysms before symptoms appear, running on optimized MRI hardware, proprietary imaging software, and AI-powered insights. Each scan captures 1.3 billion data points and screens for hundreds of conditions across major organ systems, without radiation or contrast agents, in under an hour.

The engineering scope is substantial. The company's technical work spans medical imaging, proprietary imaging software, optimized MRI hardware, and machine learning applied to healthcare diagnostics. Over 100,000 scans have been completed, with more than 170,000 patients served and potentially life-saving findings in 1 in 20 scans - a body of real-world imaging data at a scale few diagnostic platforms reach.

Prenuvo employs more than 200 healthcare professionals, including radiologists, MRI technologists, and preventative health physicians, working alongside the technical teams. Backed by a $120M Series B, the company operates across North America and the United Kingdom, with international expansion under way. The stated aim is to shift care from reactive treatment toward prevention, giving individuals the information to act on their health early.